Answers are grounded in this paper and cite their sources.
The in vivo expression of proteins by mRNA therapeutics is a transformative approach to medicine that involves expressing highly complex and therapeutically relevant molecules utilizing patients' own body. In this study, we engineered complex molecules targeting CD47 with multivalent SIRPα-Fc fusion proteins with a goal to enhance tumor specificity via formulated mRNA administration. Valency allows us to exploit antigen expression level differences between cancer and healthy cells. In vitro analysis showed that NK-mediated cytotoxicity of Tetravalent and Octavalent SIRPα was comparable to a 50,000-fold affinity-improved SIRPα molecule. However, unlike the affinity-improved SIRPα and known anti-CD47 antibodies, the Tetravalent and Octavalent SIRPα showed low to no binding to red blood cells, which also express CD47 albeit at a low level. In addition, we demonstrated in vivo efficacy of mRNAs encoding Tetravalent and Octavalent SIRPα-Fc fusion proteins and observed the complete eradication of established subcutaneous tumors in Raji mice xenograft. Further evaluation of the in-vivo-expressed proteins showed high purity, like that of the recombinant production. Differential scanning fluorimetry analysis revealed excellent thermal stability and resistance to aggregation. These results demonstrate that a significant enhancement in therapeutic window and efficacy could be achieved by engineering complex multivalent molecules.
No takes yet. Share an insight, caveat, or question.
Lal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: